Ms. Samira Sakhia reports

NOTICE OF KNIGHT THERAPEUTICS' FIRST QUARTER 2023 RESULTS CONFERENCE CALL

Knight Therapeutics Inc. will release its first quarter 2023 financial results on Thursday, May 11, 2023, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date:  Thursday, May 11, 2023

Time:  8:30 a.m. ET

Telephone:   1-855-669-9657 (toll-free) or 1-412-317-0790 (international)

Webcast:  on the Knight Therapeutics website

This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay

An archived replay will be available for 30 days on Knight Therapeutics' website.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.